Logo Image

Authors

Jane de Lartigue, PhD
Latest Article

Early Data Make B7-H3 a Checkpoint Contender in Prostate Cancer and Beyond

B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.

Jane Hall, PhD
Latest Article

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Janet Pregler, MD
Latest Article

Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors

For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.

Janey C. Peterson, MA, MS, RN, EdD
Latest Article

There's an App for That: Keeping Patients and Physicians on Track

In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.

Janice P. Dutcher, MD, Cytokine Working Group
Janice Shen, MD
Latest Article

Overcoming Burnout as an Oncology Fellow

Janice Shen, MD, provides advice on how to overcome burnout in order to provide the best care possible for patients with cancer.

Jared M. Weiss, MDUniversity of North Carolina School of Medicine
Jared Weiss, MD, UNC School of Medicine
Jared Weiss, MD, University of North Carolina School of Medicine
Jasmine Kamboj, MD
Latest Article

The Loss of My Friend

Every medical specialty is a unique subject, and oncology is no exception. Despite the vastness and depth that it entails, it resorts to some of the most universal laws of “being human.”

Jason Astrin, PA-C, MBA, DFAAPA
Latest Article

A Collaborative Model for Advanced Practice Providers Empowers Success

The burden on oncologists is becoming unmanageable, leading many practices to turn to advanced practice providers.

Jason Broderick
Latest Article

Nogapendekin Alfa Inbakicept Plus BCG Favored Over Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

In an indirect comparison, NAI+BCG showed numerically higher, significantly longer responses and a trend toward greater bladder preservation vs nadofaragene.

Jason E. Sandler, MD
Latest Article

Early-Stage NSCLC Is Ripe for Change

Following a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.

Jason H. Mendler, MD, PhD
Latest Article

Life Persists: One Fellow Finds Hope Amid Cancer's Destruction

It was midnight and I had just been jarred out of a sound sleep by the startlingly repetitive beeping of my pager.

Jason Harris, OncLive
Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: [email protected]


Latest Article

Adding Patient-Specific Comorbidities May Improve Risk Evaluation in Myelofibrosis

Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.

Jason J. Luke, MD, FACP, University of Chicago
Jason J. Luke, MD, FACP, University of Chicago Medicine
Jason J. Luke, MD, FACP, UPMC Hillman Cancer Center
Jason J. Luke, MD, University of Chicago
Jason M. Broderick
Latest Article

Imlunestrant With/Without Abemaciclib Maintains PFS, OS Benefit in ER+/HER2– Breast Cancer

Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.

Jason Y. Cheng, PhD
Latest Article

Primary Radiation Therapy for Myeloid Sarcoma of the Porta Hepatis

Treating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.

Jatin J. Shah, MD, MD Anderson Cancer Center
Jatin J. Shah, MD, The University of Texas MD Anderson Cancer Center
Jatin P. Shah, MD, MD Anderson Cancer Center
Javier A. Pinilla-Ibarz, MD, PhD, H. Lee Moffitt Cancer Center
Javier Munoz, MD, FACP, Banner MD Anderson Cancer Center
Javier Pinilla-Ibarz, MD, PhD, H. Lee Moffitt Cancer Center
Javier Pinilla-Ibarz, MD, PhD, Moffitt Cancer Center
Jaya V. Juturi, MD
Latest Article

Do You Have the Right Tools?: How IT adoption can enhance your practice

True integration of cutting-edge care and timely translation of information from the bench to bedside requires an oncology practice to have knowledgeable physicians and a "toolbox of technology."

Jean-Yves Blay, MD, PhD, Centre Leon Berard